Botanical Extracts and Migraine Headaches

Several botanical compounds have been studied for their potential role in influencing migraine frequency and severity. Two of the most frequently researched herbs in this area are butterbur (Petasites hybridus) and feverfew (Tanacetum parthenium). The following studies highlight how these botanicals have been evaluated in controlled research settings.

Butterbur Extract in Children and Adolescents

Research published in Headache (2005; 45(3):196–203) examined the effects of butterbur root extract in children and adolescents with migraine headaches. Study participants ranged in age from 6 to 17 years and had a history of migraines lasting at least one year.

Butterbur extract was administered daily for four months, with dosages ranging from 50 to 150 mg per day, adjusted according to body weight. Participants recorded migraine frequency and symptoms in headache journals throughout the study.

At the conclusion of the study, 77% of participants experienced a reduction in migraine episodes of at least 50%, and 91% reported overall improvement in symptoms. These findings suggest that butterbur extract may influence migraine patterns in a subset of pediatric patients.

Feverfew Extract in Adult Migraine

A double-blind, placebo-controlled study published in The Lancet (July 23, 1998; 189–192) evaluated the effects of a feverfew extract on migraine frequency and severity in adults. The study lasted four months, with complete data available for 59 participants.

Compared with placebo, participants receiving feverfew experienced fewer migraine attacks and reduced severity of symptoms during the study period. The results support earlier observations that feverfew may affect migraine frequency in some individuals.

Context and Interpretation

Together, these studies suggest that certain botanicals may influence migraine frequency in specific populations, though responses vary and mechanisms remain incompletely understood. Importantly, these effects appear to occur outside of conventional pharmaceutical pathways, and they may not apply to all individuals with migraines.

This draft is intended as a research summary only and does not establish clinical recommendations.